Poniard Pharma (PARD) Rips on FAK Licensing Deal Announcement
Tweet
Share
E-mail
Making the most impressive move on the day is Poniard Pharmaceuticals (Nasdaq: PARD).
Earlier in the session, Poniard announced it entered into a licensing agreement with an undisclosed party for rights to Poniard's focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK.
Poniard will get $250,000 upfront, plus milestone payments and other considerations.
On the report, Poniard moved as much as 200 percent higher on the session, and is up 120 percent into the close.
Earlier in the session, Poniard announced it entered into a licensing agreement with an undisclosed party for rights to Poniard's focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK.
Poniard will get $250,000 upfront, plus milestone payments and other considerations.
On the report, Poniard moved as much as 200 percent higher on the session, and is up 120 percent into the close.
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
